Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence

Clinical Therapeutics

Volumn 35, Issue 6, 2013, Pages 836-845

  Patrick, Donald L ^a   Khalaf, Kristin M ^b   Dmochowski, Roger ^c   Kowalski, Jonathan W ^b   Globe, Denise R ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ALLERGAN INC   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

I QOL; OnabotulinumtoxinA; Overactive bladder; Psychometrics; Quality of life; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; AGED; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EFFECT SIZE; FEMALE; HUMAN; INCONTINENCE QUALITY OF LIFE INSTRUMENT; MALE; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL; PSYCHOMETRY; QUALITY OF LIFE INDEX; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; REPRODUCIBILITY; SYMPTOM; URINE INCONTINENCE; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; QUALITY OF LIFE; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; YOUNG ADULT;

EID: 84879463497     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.04.013     Document Type: Article

References (28)

1. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003, 62(5 Suppl 2):28-37. Discussion 40-22.
2. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004, 64(6 Suppl 1):2-6.
3. Barry M.J., Cockett A.T., Holtgrewe H.L., et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993, 150(2 Pt 1):351-358.
4. de la Rosette J.J., Witjes W.P., Schäfer W., et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-"BPH" study. Neurourol Urodyn 1998, 17:99-108.
5. Reynard J.M., Yang Q., Donovan J.L., et al. The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998, 82:619-623.
6. Naughton M.J., Donovan J., Badia X., et al. Symptom severity and QOL scales for urinary incontinence. Gastroenterology 2004, 126(1 Suppl 1):S114-S123.
7. Abrams P., Cardozo L., Chapple C., et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006, 13:692-698.
8. Coyne K.S., Tubaro A., Brubaker L., Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006, 68(2 Suppl):9-16.
9. Wagner T.H., Patrick D.L., Bavendam T.G., et al. Quality of life of persons with urinary incontinence: development of a new measure. Urology 1996, 47:67-71. Discussion 71-62.
10. Patrick D.L., Martin M.L., Bushnell D.M. The I-QOL: A Quality-of-Life Instrument Specific to Persons With Urinary Incontinence: User's Manual and Scoring Diskette for United States Version 1999, Health Research Associates, Inc, Seattle, Wash.
11. Norton P.A., Zinner N.R., Yalcin I., Bump R.C. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002, 187:40-48. for the Duloxetine Urinary Incontinence Study Group.
12. Dmochowski R.R., Miklos J.R., Norton P.A., et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003, 170(4 Pt 1):1259-1263.
13. Millard R.J., Moore K., Rencken R., et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. Br J Urol Int 2004, 93:311-318. For the Duloxetine UI Study Group.
14. van Kerrebroeck P., Abrams P., Lange R., et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynaecol 2004, 111:249-257.
15. Schurch B., Denys P., Kozma C.M., et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 2007, 88:646-652.
16. Patrick D.L., Martin M.L., Bushnell D.M., et al. Quality of life of women with urinary incontinence: further development of the Incontinence Quality Of Life Instrument (I-QOL). Urology 1999, 53:71-76.
17. Bushnell D.M., Martin M.L., Summers K.H., et al. Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL. Qual Life Res 2005, 14:1901-1913.
18. Patrick D.L., Martin M.L., Bushnell D.M., et al. Cultural adaptation of a quality-of-life measure for urinary incontinence. Eur Urol 1999, 36:427-435.
19. US Food and Drug Administration Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research 2009, Federal Register FR Doc, Rockville, Md, E9-29273.
20. Dmochowski R., Chapple C., Nitti V.W., et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010, 184:2416-2422.
21. Kelleher C.J., Cardozo L.D., Khullar V., Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997, 104:1374-1379.
22. Jaeschke R., Singer J., Guyatt G.H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989, 10:407-415.
23. Ware J.E., Kosinski M., Bjorner J.B., et al. User's Manual for the SF-36v2TM Health Survey 2007, QualityMetric Inc, Lincoln, RI. 2nd ed.
24. Bentler P.M. Comparative fit indexes in structural models. Psychol Bull 1990, 107:238-246.
25. Hu L., Bentler P.M. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Modeling 2009, 6:1-55.
26. Scientific Advisory Committee of the Medical Outcomes Trust Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res May 2002, 11:193-205.
27. Campbell J.D., Gries K.S., Watanabe J.H., et al. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol 2009, 9:18.
28. Brenner M.H., Curbow B., Legro M.W. The proximal-distal continuum of multiple health outcome measures: the case of cataract surgery. Med Care 1995, 33(4 Suppl):AS236-AS244.